Author

B. Bosnjak

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 3 Organism:mouse· 3 Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1 Approach:genetic perturbation / CRISPR· 1 Assay:imaging· 1

Frequent Co-Authors

R. Foerster· 3 shared A. Schimrock· 2 shared C. Ritter· 2 shared K. Wagner· 2 shared M. Messerle· 2 shared S. Willenzon· 2 shared Y. Lueder· 2 shared A. Freudenstein· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

R. Foerster

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Protective function of ex vivo expanded CD8 T cells in a mouse model of adoptive therapy for cytomegalovirus infection depends on integrin beta 1 but not CXCR3, CTLA4, or PD-1 expression

X. Liu, R. Gutierrez Jauregui, Y. Lueder, S. Halle, L. Ospina-Quintero, C. Ritter, A. Schimrock, S. Willenzon, A. Janssen, K. Wagner, M. Messerle, B. Bosnjak, R. Foerster

bioRxiv · Mar 16, 2024 · PreprintImmunology

MHC class Ia molecules facilitate MCK2-dependent MCMV infection of macrophages and virus dissemination to the salivary gland

B. Bosnjak, E. Henze, Y. Lueder, K. T. H. Do, A. Rezalofti, C. Ritter, A. Schimrock, S. Willenzon, H. Georgiev, L. Fritz, M. Galla, K. Wagner, M. Messerle, R. Foerster

This study identifies the MHC-Ia/B2m complex as a receptor for MCK2-mediated MCMV infection of macrophages and shows its role in viral dissemination to salivary glands.

bioRxiv · Oct 5, 2022Immunology

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination

A. Tscherne, J. H. Schwarz, C. Rohde, A. Kupke, G. Kalodimou, L. Limpinsel, N. M. A. Okba, B. Bosnjak, I. Sandrock, S. Halwe, L. Sauerhering, K. Printz, L. Nan, E. Duell, S. Jany, , A. Volz

This paper describes the preclinical evaluation of MVA-SARS-2-S, a vector vaccine against SARS-CoV-2, showing it induces immune responses and protects mice from infection.

bioRxiv · Jan 9, 2021Microbiology